TD Waterhouse Canada’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

TD Waterhouse Canada’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-33	Closed	-$3.36K	–	1822
2023 Q2	$3.36K	Hold	33	–	–	﹤0.01%	1458
2023 Q1	$3.1K	Hold	33	–	–	﹤0.01%	1457
2022 Q4	$1.21K	Hold	33	–	–	﹤0.01%	1543
2022 Q3	$855	Hold	33	–	–	﹤0.01%	1589
2022 Q2	$1K	Hold	33	–	–	﹤0.01%	1619
2022 Q1	$1.17K	Buy	+33	New	+$979	﹤0.01%	1658

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TD Waterhouse Canada's RETA Position: Q3 2023 in Review

TD Waterhouse Canada sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 33 shares — an estimated $3.36K sold.

TD Waterhouse Canada first reported a position in RETA in Q1 2022 and held it in 6 quarters. The position peaked at $3.36K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

TD Waterhouse Canada reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
TD Waterhouse Canada sold 33 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $3.36K.
TD Waterhouse Canada first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2022 and held it in 6 quarters.
TD Waterhouse Canada's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.36K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on TD Waterhouse Canada's 13F filing for Q3 2023, filed 13 Nov 2023.